10X Genomics Inc (TXG)

Currency in USD
14.01
-0.27(-1.89%)
Closed·
14.19+0.18(+1.28%)
·
TXG Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TXG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.9714.43
52 wk Range
6.7824.76
Key Statistics
Prev. Close
14.28
Open
14.29
Day's Range
13.97-14.43
52 wk Range
6.78-24.76
Volume
1.57M
Average Volume (3m)
3.64M
1-Year Change
-40%
Book Value / Share
6.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TXG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.08
Upside
+7.62%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

10X Genomics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

10X Genomics Inc Company Profile

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

10X Genomics Inc SWOT Analysis


Golden Prospects
Torex Gold transitions to positive cash flow as Media Luna project ramps up, positioning the company for growth amid rising gold prices and market interest
Operational Milestones
Explore Torex's rapid progress at Media Luna, with commercial production achieved and ambitious mining rate targets set to outpace initial projections
Market Dynamics
Delve into how Torex's lean financial structure may appeal to investors seeking exposure to gold's upward trend, with price targets ranging from $35 to $56
Navigating Challenges
Learn about Torex's resilience in overcoming recent setbacks, including production disruptions, while maintaining its annual guidance and focusing on safety
Read full SWOT analysis

10X Genomics Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $0.28 beats -$0.37 forecast; revenue reaches $173M, up 13% YoY; net income of $34.5M vs $37.9M loss in 2024
  • Gross margin improves to 72%; strong consumables growth offsets 39% decline in instrument revenue; cash balance at $447M
  • Stock falls 2.92% post-earnings despite positive results; company maintains 'GOOD' financial health score of 2.79/5
  • Q3 revenue guidance: $140M-$144M; recent Scale Biosciences acquisition expected to have minimal near-term revenue impact
  • Uncertain funding landscape affecting customer spending; challenges in global capital equipment purchases noted as ongoing risks
Last Updated: 21/08/2025, 23:04
Read Full Transcript

Compare TXG to Peers and Sector

Metrics to compare
TXG
Peers
Sector
Relationship
P/E Ratio
−20.6x−3.0x−0.5x
PEG Ratio
−0.31−0.370.00
Price/Book
2.3x1.4x2.6x
Price / LTM Sales
2.7x2.1x3.2x
Upside (Analyst Target)
7.1%23.6%37.1%
Fair Value Upside
Unlock19.1%5.4%Unlock

Analyst Ratings

7 Buy
9 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 15.08
(+7.62% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
0.28 / -0.37
Revenue / Forecast
172.90M / 139.40M
EPS Revisions
Last 90 days

TXG Income Statement

People Also Watch

-
TEM
+0.00%
-
BEAM
0.00%
-
TWST
+0.00%
-
GTLB
0.00%

FAQ

What Stock Exchange Does 10X Genomics Trade On?

10X Genomics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for 10X Genomics?

The stock symbol for 10X Genomics is "TXG."

What Is the 10X Genomics Market Cap?

As of today, 10X Genomics market cap is 1.74B.

What Is 10X Genomics's Earnings Per Share (TTM)?

The 10X Genomics EPS (TTM) is -0.69.

When Is the Next 10X Genomics Earnings Date?

10X Genomics will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is TXG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has 10X Genomics Stock Split?

10X Genomics has split 0 times.

How Many Employees Does 10X Genomics Have?

10X Genomics has 1306 employees.

What is the current trading status of 10X Genomics (TXG)?

As of 01 Sept 2025, 10X Genomics (TXG) is trading at a price of 14.01, with a previous close of 14.28. The stock has fluctuated within a day range of 13.97 to 14.43, while its 52-week range spans from 6.78 to 24.76.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.